ofloxacin has been researched along with Tuberculosis, Multidrug-Resistant in 145 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 5.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| "Ofloxacin and moxifloxacin are the most commonly used fluoroquinolones (FQs) for the treatment of tuberculosis." | 3.85 | Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis. ( Bao, L; Luo, T; Mi, Y; Peng, X; Sun, C; Wang, C; Yang, G; Yuan, J; Zhang, C, 2017) |
| " Further studies should determine the optimal pharmacodynamic target for moxifloxacin in a multidrug regimen and clarify safety issues when it is administered at higher doses." | 2.79 | Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. ( Charalambous, S; Chigutsa, E; Denti, P; Harrison, T; Hatherill, M; Jindani, A; McIlleron, HM; Mungofa, S; Simonsson, US; Sirgel, FA; Wiesner, L; Zvada, SP, 2014) |
| "Despite the important role of fluoroquinolones and the predominant use of ofloxacin for treating multidrug-resistant tuberculosis in South Africa, there are limited data on ofloxacin pharmacokinetics in patients with multidrug-resistant tuberculosis, no ofloxacin pharmacokinetic data from South African patients, and no direct assessment of the relationship between ofloxacin pharmacokinetics and the MIC of ofloxacin of patient isolates." | 2.77 | Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. ( Chigutsa, E; Harding, J; Kirkpatrick, CM; Mac Kenzie, WR; McIlleron, H; Meredith, S; Moodley, P; Padayatchi, N; Weiner, M; Wiesner, L, 2012) |
| "After the completion of the treatment course, the negative sputum conversion rate in V+D+M treatment protocol group was 84%, significantly higher than that in the control group (42%); the former group showed a focal absorption rate and pulmonary cavity closure rate of 83% and 66%, which were 33% and 26% respectively in the latter." | 2.71 | [Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis]. ( Li, SM; Xing, BC; Zheng, XM, 2004) |
| " We aim to compare the culture conversion between new-generation (levofloxacin and moxifloxacin) and old-generation (ciprofloxacin and ofloxacin) fluoroquinolones, develop pharmacokinetic models, and calculate target attainment for levofloxacin and moxifloxacin." | 1.51 | Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. ( Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA, 2019) |
| " Adverse events associated with second-line drugs (SLDs) can have severe impact on efficient management." | 1.43 | Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis. ( Hosmane, GB; Jain, A; Kushwaha, RA; Prasad, R; Singh, A; Srivastava, R, 2016) |
| "Ofloxacin was safe and well tolerated in children with MDR-TB, but exposures were well below reported adult values, suggesting that dosage modification may be required to optimize MDR-TB treatment regimens in children." | 1.42 | Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. ( Castel, S; Dooley, KE; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Schaaf, HS; Seddon, JA; Thee, S; Wiesner, L, 2015) |
| " Drug exposures were lower than those in adults following standard doses and below the proposed pharmacodynamic targets, likely due to more rapid elimination in children." | 1.40 | Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. ( Castel, S; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Norman, J; Schaaf, HS; Thee, S; van der Merwe, PL; Wiesner, L, 2014) |
| "Verapamil and reserpine were included to determine their effect on rifampicin and ofloxacin susceptibility." | 1.37 | Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. ( Gey van Pittius, NC; Grobbelaar, M; Hernandez-Pando, R; Jimenez, A; Leon, R; Louw, GE; McEvoy, CR; Murray, M; van Helden, PD; Victor, TC; Warren, RM, 2011) |
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 1.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| " Mean +/- SD of Cmax was 9." | 1.32 | Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. ( Chierakul, N; Chindavijak, B; Chulavatnatol, S; Klomsawat, D, 2003) |
| "Levofloxacin was found to be more efficacious than ofloxacin when incorporated into multidrug regimens used for treatment of MDR-TB." | 1.32 | Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. ( Chan, CK; Chau, CH; Lee, J; Leung, CC; Tam, CM; Wong, PC; Yew, WW, 2003) |
| "Ofloxacin has been advocated by the WHO in case of MDR-TB, when susceptibility to test results are not available before starting the new treatment, in the continuation period (18 months) and if resistance is proven to at least isoniazid and rifampicin." | 1.32 | Ofloxacin in multidrug resistant tuberculosis. ( Gawde, AS; Morye, VK; Walwaikar, PP, 2003) |
| "We report a chronic case of pulmonary tuberculosis in a Malagasy citizen from Antsohihy (West of Madagascar), who was infected with a multi-drug resistant Mycobacterium bovis strain." | 1.32 | [A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar]. ( Andrianasolo, D; Ramarokoto, H; Ramaroson, F; Rasolofo Razanamparany, V; Rasolonavalona, T; Ratsimba, L; Razafitsiarovana, I; Vincent, V, 2003) |
| " This case series describes the probable association between multiple adverse events and the use of pyrazinamide and levofloxacin in the treatment of individuals with suspected latent multidrug-resistant tuberculosis infection." | 1.31 | Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. ( Dolovich, LR; Holbrook, A; Loeb, M; Papastavros, T; Whitehead, L, 2002) |
| "Treatment with ofloxacin in a combined regimen achieved a success rate of 78%." | 1.30 | Quinolones and multidrug-resistant tuberculosis. ( Maranetra, KN, 1999) |
| "Ciprofloxacin was used primarily to treat Mycobacterium avium complex (MAC) infection, dosed to achieve 2-hour post-dose serum concentrations of 4-6 micrograms/ml." | 1.29 | Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. ( Berning, SE; Iseman, MD; Madsen, L; Peloquin, CA, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (15.17) | 18.2507 |
| 2000's | 38 (26.21) | 29.6817 |
| 2010's | 73 (50.34) | 24.3611 |
| 2020's | 12 (8.28) | 2.80 |
| Authors | Studies |
|---|---|
| Sureram, S | 1 |
| Senadeera, SP | 1 |
| Hongmanee, P | 1 |
| Mahidol, C | 1 |
| Ruchirawat, S | 1 |
| Kittakoop, P | 1 |
| Rahman, SMM | 1 |
| Nasrin, R | 1 |
| Rahman, A | 1 |
| Ahmed, S | 2 |
| Khatun, R | 1 |
| Uddin, MKM | 1 |
| Rahman, MM | 1 |
| Banu, S | 2 |
| Wu, X | 1 |
| Tan, G | 1 |
| Sha, W | 1 |
| Liu, H | 1 |
| Yang, J | 1 |
| Guo, Y | 1 |
| Shen, X | 1 |
| Wu, Z | 1 |
| Shen, H | 1 |
| Yu, F | 2 |
| Jia, QJ | 1 |
| Zeng, MC | 1 |
| Xie, L | 1 |
| Cheng, QL | 1 |
| Huang, YY | 1 |
| Li, QC | 1 |
| Wu, YF | 1 |
| Ai, LY | 1 |
| Lu, M | 1 |
| Fang, ZJ | 1 |
| Sy, KTL | 1 |
| Leavitt, SV | 1 |
| de Vos, M | 1 |
| Dolby, T | 1 |
| Bor, J | 1 |
| Horsburgh, CR | 1 |
| Warren, RM | 4 |
| Streicher, EM | 2 |
| Jenkins, HE | 1 |
| Jacobson, KR | 2 |
| Pietersen, E | 1 |
| Anderson, K | 1 |
| Cox, H | 2 |
| Dheda, K | 2 |
| Bian, A | 1 |
| Shepherd, BE | 1 |
| Sterling, TR | 2 |
| van der Heijden, YF | 1 |
| Hu, Y | 3 |
| Chi, Y | 1 |
| Feng, X | 1 |
| Li, H | 1 |
| Shang, Y | 1 |
| Pan, J | 1 |
| Pang, Y | 3 |
| Herricks, T | 1 |
| Donczew, M | 1 |
| Mast, FD | 1 |
| Rustad, T | 1 |
| Morrison, R | 1 |
| Sherman, DR | 1 |
| Aitchison, JD | 1 |
| Gupta, A | 2 |
| Sinha, P | 2 |
| Rathod, S | 2 |
| Shanmugam, SK | 1 |
| Uma Devi, KR | 1 |
| Anupurba, S | 2 |
| Nema, V | 2 |
| Sayadi, M | 1 |
| Zare, H | 1 |
| Jamedar, SA | 1 |
| Hashemy, SI | 1 |
| Meshkat, Z | 1 |
| Soleimanpour, S | 1 |
| Hoffner, S | 3 |
| Ghazvini, K | 1 |
| Safari, M | 1 |
| Moghim, S | 1 |
| Salehi, M | 1 |
| Jafari, R | 1 |
| Nasr Esfahani, B | 1 |
| Davies Forsman, L | 1 |
| Niward, K | 1 |
| Kuhlin, J | 1 |
| Zheng, X | 2 |
| Zheng, R | 2 |
| Ke, R | 1 |
| Hong, C | 1 |
| Werngren, J | 2 |
| Paues, J | 1 |
| Simonsson, USH | 1 |
| Eliasson, E | 1 |
| Xu, B | 2 |
| Alffenaar, JW | 1 |
| Schön, T | 1 |
| Bruchfeld, J | 1 |
| Liu, Q | 1 |
| Yang, D | 1 |
| Qiu, B | 1 |
| Martinez, L | 1 |
| Ji, Y | 1 |
| Song, H | 1 |
| Li, Z | 1 |
| Wang, J | 1 |
| Wang, Z | 1 |
| Xie, T | 1 |
| Mu, C | 1 |
| Wang, C | 2 |
| Ju, H | 1 |
| Zhao, H | 1 |
| Sun, R | 1 |
| Luo, T | 1 |
| Yuan, J | 1 |
| Peng, X | 1 |
| Yang, G | 1 |
| Mi, Y | 1 |
| Sun, C | 1 |
| Zhang, C | 1 |
| Bao, L | 1 |
| Bablishvili, N | 2 |
| Tukvadze, N | 2 |
| Shashkina, E | 1 |
| Mathema, B | 1 |
| Gandhi, NR | 1 |
| Blumberg, HM | 2 |
| Kempker, RR | 3 |
| Guglielmetti, L | 1 |
| Varaine, F | 1 |
| Huerga, H | 1 |
| Bonnet, M | 1 |
| Rich, ML | 1 |
| Mitnick, CD | 3 |
| Arora, J | 1 |
| Kumar, G | 1 |
| Verma, AK | 1 |
| Bhalla, M | 1 |
| Singhal, R | 1 |
| Sarin, R | 1 |
| Myneedu, VP | 1 |
| Alene, KA | 1 |
| Yi, H | 1 |
| Viney, K | 1 |
| McBryde, ES | 2 |
| Yang, K | 1 |
| Bai, L | 1 |
| Gray, DJ | 1 |
| Clements, ACA | 1 |
| Xu, Z | 1 |
| Pal, SK | 1 |
| Pandey, D | 1 |
| Fakir, NA | 1 |
| Sinha, D | 1 |
| SivaKumar, S | 1 |
| Periera, M | 1 |
| Balgam, S | 1 |
| Sekar, G | 2 |
| UmaDevi, KR | 1 |
| Mamatha, HG | 1 |
| Shanthi, V | 1 |
| Atif, M | 2 |
| Bashir, A | 1 |
| Ahmad, N | 6 |
| Fatima, RK | 1 |
| Saba, S | 1 |
| Scahill, S | 1 |
| Liang, YP | 1 |
| Chen, Y | 2 |
| Xiao, TY | 1 |
| Xia, Q | 2 |
| Liu, HC | 2 |
| Zhao, XQ | 2 |
| Zeng, CY | 1 |
| Zhao, LL | 2 |
| Wan, KL | 2 |
| Yang, Y | 2 |
| Niehaus, KE | 1 |
| Walker, TM | 1 |
| Iqbal, Z | 1 |
| Walker, AS | 1 |
| Wilson, DJ | 1 |
| Peto, TEA | 1 |
| Crook, DW | 1 |
| Smith, EG | 1 |
| Zhu, T | 1 |
| Clifton, DA | 1 |
| Oudghiri, A | 1 |
| Karimi, H | 1 |
| Chetioui, F | 1 |
| Zakham, F | 1 |
| Bourkadi, JE | 1 |
| Elmessaoudi, MD | 1 |
| Laglaoui, A | 1 |
| Chaoui, I | 1 |
| El Mzibri, M | 1 |
| de Oliveira, LP | 1 |
| Carneiro, ZA | 1 |
| Ribeiro, CM | 1 |
| Lima, MF | 1 |
| Paixão, DA | 1 |
| Pivatto, M | 1 |
| de Souza, MVN | 1 |
| Teixeira, LR | 1 |
| Lopes, CD | 1 |
| de Albuquerque, S | 1 |
| Pavan, FR | 1 |
| Guerra, W | 1 |
| Javaid, A | 5 |
| Afridi, AK | 3 |
| Basit, A | 3 |
| Khan, AH | 4 |
| Ahmad, I | 3 |
| Doan, TN | 1 |
| Cao, P | 1 |
| Emeto, TI | 1 |
| McCaw, JM | 1 |
| Al-Shaer, MH | 1 |
| Alghamdi, WA | 1 |
| Alsultan, A | 1 |
| An, G | 1 |
| Alkabab, Y | 1 |
| Barbakadze, K | 1 |
| Houpt, E | 1 |
| Kipiani, M | 1 |
| Mikiashvili, L | 1 |
| Cegielski, JP | 1 |
| Heysell, SK | 2 |
| Peloquin, CA | 7 |
| Ahmed, I | 1 |
| Jabeen, K | 1 |
| Inayat, R | 1 |
| Hasan, R | 2 |
| Jnawali, HN | 1 |
| Hwang, SC | 1 |
| Park, YK | 2 |
| Kim, H | 2 |
| Lee, YS | 1 |
| Chung, GT | 1 |
| Choe, KH | 1 |
| Ryoo, S | 1 |
| Van der Walt, M | 1 |
| Lancaster, J | 1 |
| Odendaal, R | 1 |
| Davis, JG | 1 |
| Shean, K | 1 |
| Farley, J | 1 |
| Ziganshina, LE | 3 |
| Titarenko, AF | 1 |
| Davies, GR | 1 |
| Seddon, JA | 3 |
| Hesseling, AC | 5 |
| Finlayson, H | 1 |
| Fielding, K | 1 |
| Hughes, J | 1 |
| Godfrey-Faussett, P | 1 |
| Schaaf, HS | 5 |
| Zvada, SP | 1 |
| Denti, P | 1 |
| Sirgel, FA | 1 |
| Chigutsa, E | 2 |
| Hatherill, M | 1 |
| Charalambous, S | 1 |
| Mungofa, S | 1 |
| Wiesner, L | 4 |
| Simonsson, US | 1 |
| Jindani, A | 1 |
| Harrison, T | 1 |
| McIlleron, HM | 3 |
| Mpagama, SG | 1 |
| Ndusilo, N | 1 |
| Stroup, S | 1 |
| Kumburu, H | 1 |
| Gratz, J | 1 |
| Houpt, ER | 1 |
| Kibiki, GS | 1 |
| Jo, KW | 1 |
| Lee, SD | 1 |
| Kim, WS | 1 |
| Kim, DS | 1 |
| Shim, TS | 1 |
| Maimakov, T | 1 |
| Sadykova, L | 1 |
| Kalmataeva, Z | 1 |
| Kurakpaev, K | 1 |
| Šmigelskas, K | 1 |
| Wu, XC | 1 |
| Sun, Q | 1 |
| Li, GL | 1 |
| Liu, ZG | 1 |
| Trollip, AP | 1 |
| Moore, D | 1 |
| Coronel, J | 1 |
| Caviedes, L | 1 |
| Klages, S | 1 |
| Victor, T | 1 |
| Romancenco, E | 1 |
| Crudu, V | 1 |
| Ajbani, K | 1 |
| Vineet, VP | 1 |
| Rodrigues, C | 2 |
| Jackson, RL | 1 |
| Eisenach, K | 1 |
| Garfein, RS | 1 |
| Rodwell, TC | 1 |
| Desmond, E | 1 |
| Groessl, EJ | 1 |
| Ganiats, TG | 1 |
| Catanzaro, A | 1 |
| Apsindzelashvili, R | 1 |
| Thee, S | 3 |
| Garcia-Prats, AJ | 3 |
| Castel, S | 2 |
| Norman, J | 1 |
| Draper, HR | 2 |
| van der Merwe, PL | 1 |
| Syed Sulaiman, SA | 1 |
| Adnan, AS | 1 |
| Haq, Iu | 1 |
| Shah, SS | 1 |
| Ahadi, A | 1 |
| Rautenbach, C | 1 |
| Sun, Z | 1 |
| Xu, Y | 1 |
| Sun, Y | 1 |
| Liu, Y | 1 |
| Zhang, X | 1 |
| Huang, H | 1 |
| Li, C | 2 |
| Zhang, D | 2 |
| Liu, B | 1 |
| Wang, Y | 1 |
| Dalal, A | 1 |
| Pawaskar, A | 1 |
| Das, M | 1 |
| Desai, R | 1 |
| Prabhudesai, P | 1 |
| Chhajed, P | 1 |
| Rajan, S | 1 |
| Reddy, D | 1 |
| Babu, S | 1 |
| Jayalakshmi, TK | 1 |
| Saranchuk, P | 1 |
| Isaakidis, P | 1 |
| Farhat, MR | 1 |
| Franke, MF | 1 |
| Kaur, D | 1 |
| Sloutsky, A | 1 |
| Murray, M | 2 |
| Şimşek, H | 1 |
| Tarhan, G | 1 |
| Cesur, S | 1 |
| Selvakumar, N | 1 |
| Kumar, V | 2 |
| Balaji, S | 1 |
| Prabuseenivasan, S | 1 |
| Radhakrishnan, R | 1 |
| Chandrasekaran, V | 1 |
| Kannan, T | 1 |
| Thomas, A | 2 |
| Arunagiri, S | 1 |
| Dewan, P | 2 |
| Swaminathan, S | 1 |
| Donald, PR | 2 |
| Bakuła, Z | 1 |
| Napiórkowska, A | 1 |
| Kamiński, M | 1 |
| Augustynowicz-Kopeć, E | 1 |
| Zwolska, Z | 1 |
| Bielecki, J | 1 |
| Jagielski, T | 1 |
| Dooley, KE | 1 |
| Khan, MA | 1 |
| Sulaiman, SA | 1 |
| Chien, JY | 3 |
| Chiu, WY | 2 |
| Chien, ST | 2 |
| Chiang, CJ | 1 |
| Yu, CJ | 2 |
| Hsueh, PR | 4 |
| Dong, H | 1 |
| Tan, Y | 1 |
| Deng, Y | 1 |
| Cai, X | 1 |
| Jing, H | 1 |
| Xia, H | 1 |
| Li, Q | 1 |
| Ou, X | 1 |
| Su, B | 1 |
| Li, X | 1 |
| Zhang, Z | 1 |
| Li, J | 1 |
| Zhang, J | 2 |
| Huan, S | 1 |
| Zhao, Y | 1 |
| Singhal, P | 1 |
| Dixit, P | 2 |
| Singh, P | 1 |
| Jaiswal, I | 1 |
| Singh, M | 1 |
| Jain, A | 4 |
| Forsman, LD | 1 |
| Mansjö, M | 1 |
| Prasad, R | 2 |
| Singh, A | 1 |
| Srivastava, R | 1 |
| Hosmane, GB | 1 |
| Kushwaha, RA | 2 |
| Gomez, JE | 1 |
| Haseley, N | 1 |
| Desjardins, CA | 1 |
| Earl, AM | 1 |
| Hung, DT | 1 |
| Kumar, R | 1 |
| Garg, R | 1 |
| Kant, S | 2 |
| Verma, SK | 1 |
| Kumar, S | 1 |
| Shaheen, Z | 2 |
| Zafar, A | 1 |
| Chaudry, MA | 1 |
| Qayyum, S | 1 |
| Qadeer, E | 1 |
| Agha, N | 1 |
| Rizvi, N | 1 |
| Afridi, MZ | 1 |
| Chima, MK | 1 |
| Khan, AR | 1 |
| Ghafoor, A | 1 |
| Khan, S | 1 |
| Awan, SR | 1 |
| Akhtar, S | 1 |
| Choudry, K | 1 |
| Iqbal, ZH | 1 |
| Ansarie, M | 1 |
| Mokrousov, I | 1 |
| Otten, T | 1 |
| Manicheva, O | 1 |
| Potapova, Y | 1 |
| Vishnevsky, B | 1 |
| Narvskaya, O | 1 |
| Rastogi, N | 1 |
| Cox, HS | 2 |
| Sibilia, K | 1 |
| Feuerriegel, S | 2 |
| Kalon, S | 1 |
| Polonsky, J | 1 |
| Khamraev, AK | 1 |
| Rüsch-Gerdes, S | 2 |
| Mills, C | 1 |
| Niemann, S | 2 |
| Sokolova, GB | 1 |
| Kirtaeva, OV | 1 |
| Lazareva, IaV | 1 |
| Tsybanev, AA | 1 |
| Zarkua, N | 1 |
| Karimovich, HA | 1 |
| Braker, K | 1 |
| Ramachandran, R | 4 |
| Nalini, S | 1 |
| Chandrasekar, V | 1 |
| Dave, PV | 1 |
| Sanghvi, AS | 1 |
| Wares, F | 2 |
| Paramasivan, CN | 2 |
| Narayanan, PR | 2 |
| Sahu, S | 1 |
| Parmar, M | 1 |
| Chadha, S | 1 |
| Chauhan, LS | 1 |
| Chang, KC | 1 |
| Yew, WW | 7 |
| Chan, RC | 1 |
| Poissy, J | 1 |
| Aubry, A | 1 |
| Fernandez, C | 1 |
| Lott, MC | 1 |
| Chauffour, A | 1 |
| Jarlier, V | 1 |
| Farinotti, R | 1 |
| Veziris, N | 1 |
| Louw, GE | 1 |
| Gey van Pittius, NC | 2 |
| Leon, R | 1 |
| Jimenez, A | 1 |
| Hernandez-Pando, R | 1 |
| McEvoy, CR | 1 |
| Grobbelaar, M | 1 |
| van Helden, PD | 2 |
| Victor, TC | 2 |
| Joseph, P | 1 |
| Desai, VB | 1 |
| Mohan, NS | 1 |
| Fredrick, JS | 1 |
| Raman, B | 1 |
| Lee, J | 5 |
| Lee, CH | 1 |
| Kim, DK | 1 |
| Yoon, HI | 1 |
| Kim, JY | 1 |
| Lee, SM | 2 |
| Yang, SC | 1 |
| Lee, JH | 1 |
| Yoo, CG | 2 |
| Lee, CT | 2 |
| Chung, HS | 1 |
| Kim, YW | 2 |
| Han, SK | 2 |
| Yim, JJ | 2 |
| Lai, CC | 1 |
| Tan, CK | 1 |
| Huang, YT | 1 |
| Liao, CH | 1 |
| Jeon, CY | 1 |
| Kang, H | 1 |
| Kim, M | 1 |
| Murray, MB | 1 |
| Cho, EH | 1 |
| Chen, X | 1 |
| Kong, F | 1 |
| Wang, Q | 1 |
| Gilbert, GL | 1 |
| Said, HM | 2 |
| Kock, MM | 2 |
| Ismail, NA | 2 |
| Baba, K | 2 |
| Omar, SV | 2 |
| Osman, AG | 2 |
| Hoosen, AA | 2 |
| Ehlers, MM | 2 |
| Ramos, E | 1 |
| Fissette, K | 1 |
| de Rijk, P | 1 |
| Palomino, JC | 2 |
| Martin, A | 2 |
| Pitaksajjakul, P | 1 |
| Worakhunpiset, S | 1 |
| Chaiprasert, A | 1 |
| Boonyasopun, J | 1 |
| Ramasoota, P | 1 |
| Bergval, I | 1 |
| Böttger, EC | 1 |
| Bosman, M | 1 |
| Coetzee, G | 1 |
| Anthony, RM | 1 |
| Diacon, AH | 1 |
| Pym, A | 1 |
| Grobusch, M | 1 |
| Patientia, RF | 1 |
| Mahanyele, R | 1 |
| Bantubani, N | 1 |
| Narasimooloo, R | 1 |
| De Marez, T | 1 |
| van Heeswijk, R | 1 |
| Lounis, N | 1 |
| Meyvisch, P | 1 |
| Andries, K | 1 |
| McNeeley, DF | 1 |
| Meredith, S | 1 |
| Padayatchi, N | 1 |
| Harding, J | 1 |
| Moodley, P | 1 |
| Mac Kenzie, WR | 1 |
| Weiner, M | 1 |
| McIlleron, H | 1 |
| Kirkpatrick, CM | 1 |
| Yano, S | 1 |
| Kobayashi, K | 1 |
| Ikeda, T | 2 |
| Saheer, S | 1 |
| Hassan, G | 1 |
| Parengal, J | 1 |
| Mphahlele, M | 1 |
| Lakshmi, R | 1 |
| Rahman, F | 1 |
| Chauny, JV | 1 |
| Lorrot, M | 1 |
| Prot-Labarthe, S | 1 |
| De Lauzanne, A | 1 |
| Doit, C | 1 |
| Géréral, T | 1 |
| Bourdon, O | 1 |
| Pasipanodya, J | 1 |
| Srivastava, S | 1 |
| Gumbo, T | 1 |
| Papastavros, T | 1 |
| Dolovich, LR | 1 |
| Holbrook, A | 1 |
| Whitehead, L | 1 |
| Loeb, M | 1 |
| Richeldi, L | 1 |
| Covi, M | 1 |
| Ferrara, G | 1 |
| Franco, F | 1 |
| Vailati, P | 1 |
| Meschiari, E | 1 |
| Fabbri, LM | 1 |
| Velluti, G | 1 |
| Chulavatnatol, S | 2 |
| Chindavijak, B | 2 |
| Chierakul, N | 2 |
| Klomsawat, D | 2 |
| Chen, QL | 1 |
| Chen, L | 1 |
| Yin, JJ | 1 |
| Chan, CK | 2 |
| Leung, CC | 2 |
| Chau, CH | 6 |
| Tam, CM | 2 |
| Wong, PC | 3 |
| Walwaikar, PP | 1 |
| Morye, VK | 1 |
| Gawde, AS | 1 |
| Park, SK | 1 |
| Lee, WC | 1 |
| Lee, DH | 1 |
| Han, L | 1 |
| Seung, KJ | 1 |
| Zheng, XM | 1 |
| Li, SM | 1 |
| Xing, BC | 1 |
| Kam, KM | 1 |
| Yip, CW | 1 |
| Ramarokoto, H | 1 |
| Andrianasolo, D | 1 |
| Rasolonavalona, T | 1 |
| Ramaroson, F | 1 |
| Razafitsiarovana, I | 1 |
| Vincent, V | 1 |
| Ratsimba, L | 1 |
| Rasolofo Razanamparany, V | 1 |
| Ward, HA | 1 |
| Marciniuk, DD | 1 |
| Hoeppner, VH | 1 |
| Jones, W | 1 |
| Portaels, F | 3 |
| Rafailidis, PI | 1 |
| Avramopoulos, I | 1 |
| Sapkas, G | 1 |
| Falagas, ME | 1 |
| Vizel, AA | 1 |
| Squire, SB | 2 |
| Mirsaeidi, SM | 1 |
| Tabarsi, P | 1 |
| Khoshnood, K | 1 |
| Pooramiri, MV | 1 |
| Rowhani-Rahbar, A | 1 |
| Mansoori, SD | 1 |
| Masjedi, H | 1 |
| Zahirifard, S | 1 |
| Mohammadi, F | 1 |
| Farnia, P | 1 |
| Masjedi, MR | 1 |
| Velayati, AA | 1 |
| Kim, HJ | 1 |
| Kang, CH | 1 |
| Kim, YT | 1 |
| Sung, SW | 1 |
| Kim, JH | 1 |
| Shim, YS | 1 |
| Tada, A | 1 |
| Kawata, N | 1 |
| Shibayama, T | 1 |
| Takahashi, S | 1 |
| Hirano, A | 1 |
| Kimura, G | 1 |
| Takeuchi, M | 1 |
| Okada, C | 1 |
| Soda, R | 1 |
| Takahashi, K | 1 |
| Sulochana, S | 1 |
| Narayanan, S | 1 |
| Suganthi, C | 1 |
| Umubyeyi, A | 1 |
| Rigouts, L | 1 |
| Shamputa, IC | 1 |
| Dediste, A | 1 |
| Struelens, M | 1 |
| von Gottberg, A | 1 |
| Klugman, KP | 1 |
| Cohen, C | 1 |
| Wolter, N | 1 |
| de Gouveia, L | 1 |
| du Plessis, M | 1 |
| Mpembe, R | 1 |
| Quan, V | 1 |
| Whitelaw, A | 1 |
| Hoffmann, R | 1 |
| Govender, N | 1 |
| Meiring, S | 1 |
| Smith, AM | 1 |
| Schrag, S | 1 |
| Reichman, LB | 1 |
| Elliott, AM | 1 |
| Berning, SE | 5 |
| Iseman, MD | 4 |
| Mühlberger, F | 1 |
| Nturanye, F | 1 |
| Nasbimana, J | 1 |
| Madsen, L | 1 |
| Horn, DL | 1 |
| Hewlett, D | 1 |
| Alfalla, C | 1 |
| Peterson, S | 1 |
| Opal, SM | 1 |
| Wong, CF | 1 |
| Ruggiero, SL | 1 |
| Hilton, E | 1 |
| Braun, TW | 1 |
| Maranetra, KN | 2 |
| Zhang, LX | 1 |
| Suo, J | 1 |
| Yu, MC | 1 |
| Lee, CN | 1 |
| Chiang, CY | 1 |
| Lin, TP | 1 |
| Hadiarto, M | 1 |
| Tjandra, YA | 1 |
| Hudoyo, A | 2 |
| Iwanaga, T | 1 |
| Yokota, K | 1 |
| Kishikawa, R | 1 |
| Tsurutani, H | 1 |
| Hirose, T | 1 |
| Nishima, S | 1 |
| Au, KF | 1 |
| Michałowska-Mitczuk, D | 1 |
| Kuś, J | 1 |
| Huitt, GA | 1 |
| Arora, VK | 1 |
| Tumbanatham, A | 2 |
| Ye, Z | 1 |
| Pei, X | 1 |
| Telzak, EE | 1 |
| Chirgwin, KD | 1 |
| Nelson, ET | 1 |
| Matts, JP | 1 |
| Sepkowitz, KA | 1 |
| Benson, CA | 1 |
| Perlman, DC | 1 |
| El-Sadr, WM | 1 |
| Zhang, Y | 1 |
| Qian, H | 1 |
| Chen, M | 1 |
| Mangunnegoro, H | 1 |
| Casal, M | 1 |
| Ruiz, P | 1 |
| Herreras, A | 1 |
| Cherry, TA | 1 |
| Vinodkumar, S | 1 |
| Grimaldo, ER | 1 |
| Tupasi, TE | 1 |
| Rivera, AB | 1 |
| Quelapio, MI | 1 |
| Cardaño, RC | 1 |
| Derilo, JO | 1 |
| Belen, VA | 1 |
| Tahaoğlu, K | 1 |
| Törün, T | 1 |
| Sevim, T | 1 |
| Ataç, G | 1 |
| Kir, A | 1 |
| Karasulu, L | 1 |
| Ozmen, I | 1 |
| Kapakli, N | 1 |
| Reid, J | 1 |
| Marciniuk, D | 1 |
| Hoeppner, V | 1 |
| Pracharktam, R | 1 |
| Angkananukool, K | 1 |
| Vibhagool, A | 1 |
| Padeĭskaia, EN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Plasma Drug Concentrations in the Treatment of Multidrug-resistant Tuberculosis in Relation to Minimum Inhibitory Concentrations - a Prospective Observational Study[NCT02816931] | 37 participants (Actual) | Observational | 2016-03-31 | Completed | |||
| Leveraging mHealth to Enable and Adapt Community Health Worker Strategies to Improve TB/HIV Patient Outcomes in South Africa (LEAP-TB-SA) Trial[NCT04298905] | 200 participants (Anticipated) | Interventional | 2022-03-10 | Recruiting | |||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| A Randomized Clinical Trial of Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa[NCT04618198] | Phase 3 | 436 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290] | Phase 3 | 588 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033] | Phase 3 | 650 participants | Interventional | Completed | |||
| A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in[NCT00000796] | 525 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 17 |
| Regimen C (Oral Regimen) | 4 |
| Regimen D (6-month Regimen) | 0 |
The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen B (Control Regimen) | 14 |
| Regimen D (6-month Regimen) | 2 |
The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 17 |
| Regimen B (Control Regimen) | 126 |
| Regimen C (Oral Regimen) | 152 |
| Regimen D (6-month Regimen) | 115 |
The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 5 |
| Regimen C (Oral Regimen) | 5 |
| Regimen D (6-month Regimen) | 3 |
The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 133 |
| Regimen C (Oral Regimen) | 162 |
| Regimen D (6-month Regimen) | 122 |
7 reviews available for ofloxacin and Tuberculosis, Multidrug-Resistant
| Article | Year |
|---|---|
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
Topics: Antitubercular Agents; Ciprofloxacin; Drug Substitution; Fluoroquinolones; Humans; Levofloxacin; Ofl | 2013 |
Fluoroquinolones for the treatment of tuberculosis in children.
Topics: Age Factors; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; F | 2015 |
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
Topics: Antitubercular Agents; Aza Compounds; Bacterial Proteins; DNA Gyrase; DNA, Bacterial; Drug Resistanc | 2010 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized | 2005 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized | 2008 |
Treatment of multidrug-resistant tuberculosis in Thailand.
Topics: Acquired Immunodeficiency Syndrome; Ambulatory Care Facilities; Clinical Trials as Topic; Drug Resis | 1996 |
Treatment of multidrug-resistant tuberculosis in China.
Topics: Antitubercular Agents; China; Clinical Trials as Topic; Drug Therapy; Financing, Organized; Health P | 1996 |
13 trials available for ofloxacin and Tuberculosis, Multidrug-Resistant
| Article | Year |
|---|---|
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.
Topics: Adult; Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; M | 2014 |
[Floracide, a Russian 3rd generation fluoroquinolone in complex therapy of tuberculosis].
Topics: Adult; Antitubercular Agents; Arthralgia; Diarrhea; Drug Resistance, Multiple, Bacterial; Drug Thera | 2008 |
Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India.
Topics: Adult; Antibiotics, Antitubercular; Communicable Disease Control; Cycloserine; Directly Observed The | 2011 |
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.
Topics: Antitubercular Agents; Clarithromycin; Cycloserine; Dapsone; Diarylquinolines; Erythromycin; Female; | 2012 |
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxa | 2012 |
[Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminosalicylic Acid; Aminosalicylic Acids; Clinical | 2004 |
Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran.
Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; Cycloserine; Drug Therapy, Combination; Fe | 2005 |
Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis.
Topics: Health Personnel; Humans; Occupational Diseases; Ofloxacin; Premedication; Pyrazinamide; Tuberculosi | 1994 |
Treatment of multidrug-resistant tuberculosis in Taiwan.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Drug Resistance, Multiple; Drug Therapy, C | 1996 |
Treatment of multidrug-resistant tuberculosis in Indonesia.
Topics: Adult; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Indonesia; Isoniazid; M | 1996 |
[Analysis of causes of drug resistance and therapeutic effects on 27 multi-drug resistant pulmonary tuberculosis patients].
Topics: Adult; Aminosalicylic Acid; Anti-Infective Agents; Antitubercular Agents; Drug Resistance, Multiple; | 1997 |
[Bronchofiberscope and catheter intervention in treatment of multi-drug resistant pulmonary tuberculosis].
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchoscopy; Catheterization, Periph | 1997 |
Efficacy of low-dose ofloxacin in the treatment of multidrug-resistant tuberculosis in Indonesia.
Topics: Adolescent; Adult; Anti-Infective Agents; Female; Humans; Male; Middle Aged; Ofloxacin; Treatment Ou | 1999 |
125 other studies available for ofloxacin and Tuberculosis, Multidrug-Resistant
| Article | Year |
|---|---|
Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis.
Topics: Alkaloids; Antitubercular Agents; Benzylisoquinolines; Drug Resistance, Multiple, Bacterial; Humans; | 2012 |
Performance of GenoType MTBDRsl assay for detection of second-line drugs and ethambutol resistance directly from sputum specimens of MDR-TB patients in Bangladesh.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bangladesh; DNA, Bacterial; Ethambutol; Exten | 2021 |
Use of Whole-Genome Sequencing to Predict
Topics: Amikacin; Aminosalicylic Acid; Antitubercular Agents; China; Cycloserine; Drug Resistance; Ethambuto | 2022 |
Molecular Detection of Ofloxacin and Kanamycin Resistance in Patients with MDR and Non-MDR TB from Suburban Districts in Hangzhou, China, 2019-2020.
Topics: Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuber | 2022 |
Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa.
Topics: Amikacin; Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; | 2022 |
Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
Topics: Adult; Amikacin; Aminosalicylic Acid; Antitubercular Agents; Ethionamide; Female; HIV Infections; Ho | 2023 |
Comparison of the Diagnostic Performance of MeltPro and Next-Generation Sequencing in Determining Fluoroquinolone Resistance in Multidrug-Resistant Tuberculosis Isolates.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; High-Throughput Nuc | 2023 |
ODELAM, rapid sequence-independent detection of drug resistance in isolates of
Topics: Antibiotics, Antitubercular; Colony Count, Microbial; Drug Resistance, Multiple, Bacterial; Humans; | 2020 |
Genotype analysis of ofloxacin-resistant multidrug-resistant
Topics: Adolescent; Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Female; Genotype; Hu | 2020 |
Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.
Topics: Antitubercular Agents; Codon; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fema | 2020 |
Sequence-based detection of first-line and second-line drugs resistance-associated mutations in Mycobacterium tuberculosis isolates in Isfahan, Iran.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Antitubercular Agents; Capreomycin; DNA Mutational Analysi | 2020 |
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
Topics: Antitubercular Agents; China; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; M | 2021 |
Drug resistance gene mutations and treatment outcomes in MDR-TB: A prospective study in Eastern China.
Topics: Acetyltransferases; Adult; Amidohydrolases; Antitubercular Agents; Bacterial Proteins; Catalase; Chi | 2021 |
Molecular characteristics of ofloxacin mono-resistant Mycobacterium tuberculosis isolates from new and previously treated tuberculosis patients.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bacterial Proteins; DNA Gyrase; Drug Resistan | 2018 |
Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis.
Topics: DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Genetic Fitness; Genomics; Humans; Microbi | 2017 |
Impact of
Topics: Acetyltransferases; Antitubercular Agents; Bacterial Proteins; Base Sequence; Capreomycin; DNA Gyras | 2017 |
Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; My | 2017 |
Frequency and implications of ofloxacin resistance among previously treated tuberculosis patients.
Topics: Adult; Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Humans; Male; Mycobacterium tuberc | 2017 |
Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
Topics: Adult; Antitubercular Agents; China; Cohort Studies; Extensively Drug-Resistant Tuberculosis; Female | 2017 |
PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis.
Topics: Antitubercular Agents; Base Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambut | 2017 |
Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinol | 2018 |
Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Creatinine; Drug Resistance, Multiple, Bac | 2017 |
Applied multiplex allele specific PCR to detect second-line drug resistance among multidrug-resistant tuberculosis in China.
Topics: Antitubercular Agents; Bacteriological Techniques; China; DNA Gyrase; DNA Mutational Analysis; Drug | 2017 |
Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data.
Topics: Antitubercular Agents; Ciprofloxacin; Ethambutol; Humans; Isoniazid; Machine Learning; Microbial Sen | 2018 |
Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
Topics: Amikacin; Antitubercular Agents; Base Sequence; Capreomycin; DNA Mutational Analysis; Drug Resistanc | 2018 |
Three new platinum complexes containing fluoroquinolones and DMSO: Cytotoxicity and evaluation against drug-resistant tuberculosis.
Topics: Cell Line, Tumor; Cell Survival; Ciprofloxacin; Dimethyl Sulfoxide; Drug Screening Assays, Antitumor | 2018 |
Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center Study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Cohort Studies; Drug Resistance, Bacterial; Female; | 2018 |
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; | 2018 |
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ciprofloxacin; Dose-Response Rela | 2019 |
Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
Topics: Acetamides; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Extensively Drug-R | 2013 |
Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea.
Topics: Acetyltransferases; Amidohydrolases; Amikacin; Antigens, Bacterial; Bacterial Proteins; Capreomycin; | 2013 |
Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
Topics: Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Resistance, Multiple, Bacterial; Female | 2013 |
Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study.
Topics: Antitubercular Agents; Child, Preschool; Ethambutol; Female; HIV Infections; Humans; Infant; Infant, | 2013 |
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolon | 2014 |
Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroqui | 2014 |
Treatment of tuberculosis in South Kazakhstan: clinical and economical aspects.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Capreomycin; Cycloserine; Drug Costs; Female; H | 2013 |
Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from China.
Topics: Antitubercular Agents; Bacterial Proteins; Capreomycin; Genotype; Humans; Isoniazid; Kanamycin; Micr | 2014 |
Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones | 2014 |
Performance of the MTBDRsl assay in Georgia.
Topics: Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant | 2014 |
Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Infant; Levofloxacin; Ma | 2014 |
Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study.
Topics: Adult; Antitubercular Agents; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mycoba | 2014 |
Trends in childhood drug-resistant tuberculosis in South Africa: a window into the wider epidemic?
Topics: Age Factors; Antitubercular Agents; Bacterial Proteins; Child; Child, Preschool; Drug Resistance, Mu | 2014 |
Ofloxacin resistance in Mycobacterium tuberculosis is associated with efflux pump activity independent of resistance pattern and genotype.
Topics: Antitubercular Agents; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Genotype; Micr | 2014 |
Rapid molecular screening for multidrug-resistant tuberculosis in a resource-limited region of China.
Topics: Antitubercular Agents; Bacterial Proteins; China; DNA, Bacterial; Drug Resistance, Multiple, Bacteri | 2014 |
Resistance patterns among multidrug-resistant tuberculosis patients in greater metropolitan Mumbai: trends over time.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, | 2015 |
Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.
Topics: Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tes | 2015 |
[Evaluation of second-line antituberculosis drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis complex isolates by E-test method].
Topics: Acetamides; Antitubercular Agents; Culture Media; Drug Resistance, Multiple, Bacterial; Ethionamide; | 2015 |
High rates of ofloxacin resistance in Mycobacterium tuberculosis among both new and previously treated patients in Tamil Nadu, South India.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; India; M | 2015 |
Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
Topics: Adult; Aged; Amikacin; Antitubercular Agents; Base Sequence; Capreomycin; DNA Gyrase; Drug Resistanc | 2016 |
Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; | 2015 |
Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Drug Administration Schedule; Drug Resista | 2015 |
Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Topics: Anti-Bacterial Agents; Asian People; Codon; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Europe | 2016 |
Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China.
Topics: Amikacin; China; Extensively Drug-Resistant Tuberculosis; Humans; Kanamycin; Microbial Sensitivity T | 2016 |
Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.
Topics: Aged; Antitubercular Agents; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolo | 2016 |
A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India.
Topics: Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Genotype; Humans; Ind | 2016 |
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; China; Drug Therapy, Combination; Female; | 2016 |
Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Cohort Studies; Cycloserine; Drug Therapy, Combination; Ethambutol; Et | 2016 |
Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis.
Topics: Antitubercular Agents; Clone Cells; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Evolution, Mol | 2016 |
High correlation of clinical criteria in the diagnosis of drug-resistant TB and prevalence of ofloxacin resistance.
Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuber | 2016 |
Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.
Topics: Adult; Antitubercular Agents; Communicable Disease Control; Drug Administration Schedule; Ethambutol | 2017 |
Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan.
Topics: Adolescent; Adult; Antitubercular Agents; Cross-Sectional Studies; Extensively Drug-Resistant Tuberc | 2017 |
Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia.
Topics: Antitubercular Agents; Bacterial Proteins; DNA Gyrase; Genotype; Mycobacterium tuberculosis; Ofloxac | 2008 |
Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis.
Topics: Analysis of Variance; Antitubercular Agents; Cross Infection; Extensively Drug-Resistant Tuberculosi | 2008 |
Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; Extensively Drug-Resis | 2009 |
Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.
Topics: Antitubercular Agents; Bacteriological Techniques; Colony Count, Microbial; Drug Resistance, Multipl | 2009 |
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; | 2010 |
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacterial | 2011 |
Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Topics: Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Chi-Square Distribution; Drug Res | 2011 |
Fluoroquinolone-resistant tuberculosis at a medical centre in Taiwan, 2005-10.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Drug Resistance, Bacteri | 2011 |
Clustering of Mycobacterium tuberculosis strains from foreign-born patients in Korea.
Topics: Antitubercular Agents; Cluster Analysis; DNA Transposable Elements; Emigrants and Immigrants; Female | 2011 |
Rapid detection of isoniazid, rifampin, and ofloxacin resistance in Mycobacterium tuberculosis clinical isolates using high-resolution melting analysis.
Topics: Antitubercular Agents; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Isoniaz | 2011 |
Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs.
Topics: Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; Drug Re | 2012 |
Integrated detection of multi- and extensively drug-resistant tuberculosis using the nitrate reductase assay.
Topics: Antitubercular Agents; Colorimetry; DNA Mutational Analysis; Drug Resistance, Multiple, Bacterial; E | 2012 |
gyrA and gyrB mutations in ofloxacin-resistant Mycobacterium tuberculosis clinical isolates in Thailand.
Topics: Antibiotics, Antitubercular; DNA Gyrase; Drug Resistance, Bacterial; Humans; Mutation; Mycobacterium | 2011 |
Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing.
Topics: Amikacin; Antitubercular Agents; Bacterial Typing Techniques; Base Sequence; DNA Gyrase; Drug Resist | 2012 |
Multidrug-resistant tuberculosis that required 2 years for diagnosis.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Diagnosis, Differential; Humans; Male; Ofloxacin; | 2012 |
Extra-pulmonary primary multidrug-resistant tubercular lymphadenitis in an HIV negative patient.
Topics: Adult; Antitubercular Agents; Clarithromycin; Clofazimine; Cycloserine; Diagnosis, Differential; Dru | 2012 |
Molecular characterization and second-line antituberculosis drug resistance patterns of multidrug-resistant Mycobacterium tuberculosis isolates from the northern region of South Africa.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Capreomycin; Child; Cluster Analysis; Drug Resistanc | 2012 |
Consistency of standard laboratory strain Mycobacterium tuberculosis H 37 Rv with ethionamide susceptibility testing.
Topics: Drug Resistance, Microbial; Ethionamide; Humans; Kanamycin; Microbial Sensitivity Tests; Mycobacteri | 2012 |
Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; India; Kanamycin; Kanamycin Resis | 2012 |
Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases.
Topics: Adolescent; Antitubercular Agents; Aza Compounds; Child; Child, Preschool; Female; Fluoroquinolones; | 2012 |
New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates.
Topics: Anti-Bacterial Agents; Female; Humans; Male; Ofloxacin; Tuberculosis, Multidrug-Resistant | 2012 |
Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Antitubercular Agents; Female; Humans; Levofloxacin; Male; | 2002 |
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis.
Topics: Adult; Aged; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; | 2002 |
Pharmacokinetics of ofloxacin in drug-resistant tuberculosis.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Area Under Curve; Chromatography, High Pressure | 2003 |
[A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis].
Topics: Adolescent; Adult; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Female; Humans; Le | 2003 |
Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong.
Topics: Anti-Infective Agents; Female; Hong Kong; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Retros | 2003 |
Ofloxacin in multidrug resistant tuberculosis.
Topics: Anti-Infective Agents; Comorbidity; HIV Infections; Humans; Ofloxacin; Tuberculosis, Multidrug-Resis | 2003 |
Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Cohort Studi | 2004 |
Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Communicable Disease Control; Cycloserine; D | 2004 |
[A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar].
Topics: Amikacin; Antitubercular Agents; Capreomycin; Chronic Disease; Ciprofloxacin; Cough; DNA, Bacterial; | 2003 |
Treatment outcome of multidrug-resistant tuberculosis among Vietnamese immigrants.
Topics: Capreomycin; Cycloserine; Drug Therapy, Combination; Emigration and Immigration; Ethambutol; Ethiona | 2005 |
Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays.
Topics: Anti-Bacterial Agents; Colorimetry; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; | 2005 |
Multidrug-resistant tuberculous spondylodiscitis: need for aggressive management and drug susceptibility testing of Mycobacterium tuberculosis isolates.
Topics: Anti-Bacterial Agents; Biopsy, Fine-Needle; Bone Transplantation; Cycloserine; Discitis; Drug Therap | 2006 |
Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis.
Topics: Adult; Aged; Biomarkers; Body Mass Index; Drug Resistance, Multiple, Bacterial; Female; Humans; Lung | 2006 |
[In vitro antituberculous activity of ofloxacin and levofloxacin against multidrug-resistant tuberculosis and clinical outcomes].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Drug Resistance, Multiple, Bacterial; Female; | 2006 |
Analysis of fluoroquinolone resistance in clinical isolates of Mycobacterium tuberculosis from India.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; India; Microbial Sensitivity | 2007 |
Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda.
Topics: Adult; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; Clarithromycin; Drug Resi | 2008 |
Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.
Topics: Adolescent; Anti-Bacterial Agents; Antitubercular Agents; Child; Child, Preschool; Cross Infection; | 2008 |
Tuberculosis drug resistance comes full circle.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Ofloxacin; Pneumoc | 2008 |
Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema.
Topics: Aged; Antitubercular Agents; Chronic Disease; Empyema, Tuberculous; Ethambutol; Humans; Male; Ofloxa | 1995 |
[Ofloxacin-cycloserine-protionamide-INH combination against treatment refractory lung tuberculosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Cycloserine; Dose-Response Relationship, Drug; Drug Ad | 1995 |
Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections.
Topics: Antitubercular Agents; Ciprofloxacin; Drug Administration Schedule; Female; Humans; Male; Middle Age | 1995 |
Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin.
Topics: Adult; Cycloserine; Depression; Drug Therapy, Combination; Humans; Male; Middle Aged; Ofloxacin; Sei | 1993 |
Trismus and preauricular swelling in a 20-year-old black woman.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Capreomycin; Diagnosis, Differential; Edema; Etha | 1996 |
[The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis].
Topics: Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Clavulanic | 1997 |
Advice on treatment of drug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Ciprofloxacin; Cycloserine; Drug Monitoring; Drug Resistance, Microbia | 1997 |
Levofloxacin in the treatment of drug-resistant tuberculosis.
Topics: Aged; Anti-Infective Agents; Antitubercular Agents; Drug Therapy, Combination; Follow-Up Studies; Hu | 1997 |
[Treatment of patients for chronic pulmonary tuberculosis with expectoration--selection and tolerance to drugs].
Topics: Antitubercular Agents; Chronic Disease; Drug Therapy, Combination; Drug Tolerance; Humans; Incidence | 1997 |
Levofloxacin for drug-resistant Mycobacterium tuberculosis.
Topics: Adult; Anti-Infective Agents; Drug Administration Schedule; Humans; Levofloxacin; Mycobacterium tube | 1998 |
Severe arthropathy with ofloxacin in two cases of MDR tuberculosis.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Female; Humans; Joint Diseases; Ofloxacin; Tube | 1998 |
Fluoroquinolones and tuberculosis.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Ofloxacin; Tuberculosis, Multidrug-Resistant; Tubercul | 1998 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Squa | 1999 |
Quinolones and multidrug-resistant tuberculosis.
Topics: Anti-Infective Agents; Humans; Ofloxacin; Prevalence; Thailand; Tuberculosis, Multidrug-Resistant; T | 1999 |
Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Hong Kong; Humans; Levofloxac | 2000 |
Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Drug Resistance, Microbial; Female; HIV Seropos | 2000 |
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Drug Therapy, Combination; Humans; In | 2001 |
Ofloxacin induced arthropathy in patients with multi-drug resistance tuberculosis.
Topics: Adult; Antitubercular Agents; Arthritis; Drug Interactions; Drug Therapy, Combination; Female; Human | 2000 |
Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Bronchoalveolar Lavage Fluid; Chromatography, H | 2001 |
Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines.
Topics: Anti-Infective Agents; Ciprofloxacin; Culture Media; Drug Resistance, Microbial; Drug Resistance, Mu | 2001 |
The treatment of multidrug-resistant tuberculosis in Turkey.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid | 2001 |
Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Female; Gastrostomy; Humans; Jejunostomy; Levoflo | 2002 |
In vitro susceptibility testing of levofloxacin and ofloxacin by microtiter plate Alamar blue against multidrug and non multidrug resistant Mycobacterium tuberculosis in Thailand.
Topics: Coloring Agents; Culture Media; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Microbia | 2001 |
[Combination chemotherapy of drug-resistant tuberculosis with inclusion of ofloxacin (zanocin)].
Topics: Anti-Infective Agents; Antitubercular Agents; Humans; In Vitro Techniques; Microbial Sensitivity Tes | 2001 |
Utility of fluoroquinolones in multidrug-resistant tuberculosis (MDR-TB)--a balanced view?
Topics: Ciprofloxacin; Drug Resistance, Microbial; Female; Fluoroquinolones; Humans; Male; Microbial Sensiti | 2002 |